目的 探讨生脉注射液联合重组人脑利钠肽治疗急性心力衰竭的临床效果。方法 选取2014年1月—2017年10月在中国人民解放军第二五四医院收治的112例急性心力衰竭患者，随机分为对照组和治疗组，每组各56例。对照组静脉滴注注射用重组人脑利钠肽，首次静脉冲击1.5 μg/kg，随后按照0.01 μg/（kg·min）静脉泵入。治疗组在对照组治疗基础上静脉滴注生脉注射液，50 mL生脉注射液加入到5%葡萄糖注射液100 mL，1次/d。两组均连续治疗3 d。观察两组的临床疗效，比较两组治疗前后左心室射血分数（LVEF）、左室舒张末内径（LVEDD）、尿素氮（BUN）、肌酐（Cr）、血清脑钠肽（BNP）的变化情况。结果 治疗后，对照组和治疗组的总有效率分别为78.57%、94.64%，两组比较差异有统计学意义（P < 0.05）。治疗后，两组患者LVEF显著升高，但LVEDD、BUN、Cr、BNP显著降低，同组治疗前后比较差异有统计学意义（P < 0.05）；治疗后，治疗组LVEF高于对照组，LVEDD、BUN、Cr、BNP低于对照组，两组比较差异具有统计学意义（P < 0.05）。结论 生脉注射液联合重组人脑利钠肽治疗急性心力衰竭具有显著的临床治疗效果，可明显改善患者心功能，保护肾功能，具有一定的临床推广应用价值。

Objective To investigate the clinical effect of Shengmai Injection combined with recombinant human brain natriuretic peptide in treatment of acute heart failure. Methods Patients (112 cases) with acute heart failure in No. 254 Hospital of the People's Liberation Army from January 2014 to October 2017 were randomly divided into control (56 cases) and treatment (56 cases) groups. Patients in the control group were iv administered with Recombinant Human Brain Natriuretic Peptide for injection, and the first dosage of intravenous pulse was 1.5 μg/kg, followed by 0.01 μg/(kg·min). Patients in the treatment group were iv administered with Shengmai Injection on the basis of the control group, 50 mL Shengmai Injection added to 5% glucose injection 100 mL, once daily. Patients in two groups were treated for 3 d. After treatment, the clinical efficacy was evaluated, and the changes of LVEF, LVEDD, BUN, Cr, and BNP in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the control and treatment groups were 78.57% and 94.64%, respectively, and there was difference between two groups (P < 0.05). After treatment, LVEF in two groups was elevated, but LVEDD, BUN, Cr, and BNP in two groups reduced significantly, and the difference was statistically significant in the same group (P < 0.05). After treatment, LVEF in the treatment group was higher than that in the control group, but LVEDD, BUN, Cr, and BNP were lower than those in the control group, and there was difference between two groups (P < 0.05). Conclusion Shengmai Injection combined with recombinant human brain natriuretic peptide has remarkable clinical effect in treatment of acute heart failure, and can obviously improve the heart function and protect the renal function, which has a certain clinical application value.